# Fountain Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fountain-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.fountaintx.com
- Total disclosed funding: $22M
- Latest round: Series A (Nov 18, 2021)
- Investors on record: 5

## About

Fountain Therapeutics, Inc. develops innovative therapies targeting aging-related conditions, focusing on skin and muscle atrophy to enhance patient wellness and aesthetics through advanced, non-invasive treatments.Established in 2018 and headquartered in San Francisco, US, Fountain Therapeutics, Inc. specializes in developing therapeutics for aging-related conditions. The company was founded by Joseph Rodgers, Thomas Rando, and Tom Cheung. In November 2021, the firm raised USD 15.86 mn in Series A funding from investors including Alexandria Venture Investments, Eli Lilly & Company, and Khosla Ventures, among others, achieving a total of USD 15.86 mn raised to date with a current valuation of USD 46.04 mn.Fountain Therapeutics focuses on creating first-in-class therapies for aging conditions, particularly skin and muscle atrophy. Their flagship products include FTX002600 and FTX003059, designed to combat skin atrophy by increasing subcutaneous fat in targeted areas, offering a non-invasive alternative in medical aesthetics and treating conditions such as glucocorticoid-induced skin atrophy. Additionally, FTX008762 is a small molecule modulator that preserves lean tissue and muscle mass in patients suffering from age-associated sarcopenia. The company markets its products primarily in North America and Europe, targeting healthcare providers and aesthetic clinics.Fountain Therapeutics generates revenue through partnerships and direct sales to healthcare providers and aesthetic clinics. Their revenue model is structured around B2B transactions, with healthcare professionals ordering FTX002600, FTX003059, and FTX008762 for clinical applications. Pricing and supply agreements are established based on demand forecasts, ensuring a consistent purchasing process for clinics as the company grows its market presence.Fountain Therapeutics plans to leverage the USD 15 mn raised in Series A funding from November 2021 to expand its product pipeline and enhance its team. This funding will support the development of new therapies aimed at treating aging-related conditions. The company is also considering further market expansions into additional regions, with a focus on enhancing its reach within North America and Europe. As Fountain Therapeutics enters its next growth phase, it aims to enhance its platform and offerings to meet the increasing demand for effective, non-invasive treatments.

## Funding rounds

- Series A, Nov 18, 2021, $16M — Alexandria Venture Investments, Khosla Ventures, Eli Lilly & Company, Nan Fung Life Sciences, R42
- Series A, Feb 12, 2020, $6M — Khosla Ventures, Nan Fung Life Sciences

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A
- Nan Fung Life Sciences — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Eli Lilly & Company — Series A
- R42 (https://capitalatlas.ai/funds/r42) — Series A